GenVec signed a CRADA with the NIAID to develop adenovector-based vaccines for the prevention and treatment of respiratory syncytial virus (RSV).
The collaborative research will combine NIAID's scientific and clinical expertise in RSV with GenVec's experience in development of adenovector-based vaccines and manufacturing process.
In addition to the RSV collaboration, GenVec is working with the NIAID on the clinical development of HIV and influenza vaccines. "Data emerging from the clinical trials of our HIV vaccine candidate indicates that GenVec's adenovector technology induces both antibodies and cellular immune responses," notes Rick King, GenVec's senior vp of research. "This has the potential to be highly effective in preventing RSV-induced disease."